title: A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
abstract: BACKGROUND
  BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (Fab(BO2C11)) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize FVIII by steric hindrance.
  
  
  OBJECTIVE
  The BO2C11 epitope on C2 overlaps with residues located at the periphery of the putative VWF binding site; hence, most of the residues that constitute the VWF binding site on C2 and a3 remain accessible for VWF interaction following BO2C11/FVIII complex formation. We thus investigated the contribution of alternative molecular mechanisms to FVIII inactivation by BO2C11.
  
  
  METHODS
  Continuum electrostatic calculations were applied to the crystal structure of C2, free or Fab(BO2C11)-complexed. In silico predictions were confirmed by site-directed mutagenesis and VWF-binding assays of the mutated FVIII.
  
  
  RESULTS
  Binding of Fab(BO2C11) to C2 induced perturbations in the electrostatic potential of C2 and in the local electrostatic parameters of 18 charged residues in C2, which are distant from the BO2C11 epitope. Nine of the predicted electrostatic hotspots clustered on the VWF-binding site of C2. Mutation of some of the predicted electrostatic hotspots has been associated with hemophilia A and reduced VWF binding in vitro.
  
  
  CONCLUSIONS
  Inhibitors may neutralize FVIII by alteration of protein surface electrostatics at a long distance from their epitope. Perturbation of the electrostatic environment of C2, either upon binding by anti-FVIII antibodies or consecutive to missense mutations in the F8 gene, may lead to hampered VWF binding and reduced FVIII residence time in circulation.
authors.affiliation: Centre de Recherche des Cordeliers, Université Pierre et Marie Curie - Paris6, UMR S 872, Paris, France.
authors.forename: J D
authors.initials: JD
authors.lastname: Dimitrov
authors.forename: L T
authors.initials: LT
authors.lastname: Roumenina
authors.forename: J-L
authors.initials: JL
authors.lastname: Plantier
authors.forename: S
authors.initials: S
authors.lastname: Andre
authors.forename: D
authors.initials: D
authors.lastname: Saboulard
authors.forename: Y
authors.initials: Y
authors.lastname: Meslier
authors.forename: C
authors.initials: C
authors.lastname: Planchais
authors.forename: M
authors.initials: M
authors.lastname: Jacquemin
authors.forename: J-M
authors.initials: JM
authors.lastname: Saint-Remy
authors.forename: B P
authors.initials: BP
authors.lastname: Atanasov
authors.forename: S V
authors.initials: SV
authors.lastname: Kaveri
authors.forename: S
authors.initials: S
authors.lastname: Lacroix-Desmazes
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D000939:Epitopes / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D006467:Hemophilia A; D006801:Humans; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D020125:Mutation, Missense; D055672:Static Electricity; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000939:Epitopes; D014841:von Willebrand Factor; C078147:F8 protein, human; D005169:Factor VIII